Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
CEO: Randall A. Lipps. Company website
Omnicell, Inc. (OMCL) trades at $32.23, down 1.20% on the day, as of Sep 20, 2026 14:59 UTC.
Omnicell, Inc. has a market capitalisation of $1.47B, calculated from the live OMCL share price and shares outstanding.
OMCL trades at a trailing P/E of 38.37, from earnings per share of $0.84 over the last twelve months.
Omnicell, Inc. generated revenue of $1.25B over the trailing twelve months, which puts the stock at 1.18 times sales.
OMCL has traded between $29.06 and $55.00 over the past 52 weeks, and the last price is 41.4% below that high.
Yes. Omnicell, Inc. keeps 3.13% of revenue as net income over the trailing twelve months.
Wall Street analysts rate OMCL Hold, with an average price target of $56.67, 75.8% above the current price.
Omnicell, Inc. is classified under the Healthcare sector and the Medical - Healthcare Information Services industry, and is domiciled in US.
Randall A. Lipps is the chief executive of Omnicell, Inc., which employs 3,485 people.
QFI Terminal shows OMCL with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open OMCL in Terminal See plans